ArticleBMC cancer2016

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.

Yu-Mu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.